NCT03417037

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a study of experimental medication BMS-986205 given with Nivolumab with or without chemotherapy compared to chemotherapy in participants with previously untreated stage IV or recurrent non-small cell lung cancer.

Conditions

• Lung Cancer
• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	BMS-986205	Administered orally daily, 100 mg
BIOLOGICAL	Nivolumab	Specified dose on specified days
DRUG	Chemotherapy	Platinum-based doublet chemotherapy

Timeline

• Start date: 2018-05-24
• Primary completion: 2021-04-25
• Completion: 2025-08-20
• First posted: 2018-01-31
• Last updated: 2018-04-30

Locations

83 sites across 17 countries: United States, Australia, Austria, Brazil, Canada, Czechia, France, Germany, Greece, Italy, Japan, Mexico, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye)

Regulatory

• FDA-regulated drug study